

Sponsor:	IO Biotech ApS
Protocol Number:	IO102-012
EudraCT Number:	2018-000139-28
Date of Clinical Study Report:	19 May 2023

The following table has been extracted from the final IO102-012 Clinical Study Report (dated 19 May 2023) and presents a summary of the results of the objective response rate (ORR) by baseline PD-L1 expression.

Secondary Endpoint: Objective Response Rate (ORR) by Baseline PD-L1 Expression, Cohort B.

Number of Patients (ITT Population)	Cohort B	
	Arm B1 (Phase II) + Arm B (Phase I) N=39	Arm B2 (Phase II) N=17
By PD-L1 status		
TPS <1%	n=20	n=6
Best overall response		
Complete response	0	0
Partial response	3 (15%)	2 (33.3%)
Stable disease	16 (80%)	3 (50%)
Progressive disease	1 (5%)	0
Not evaluable	0	0
Missing	0	1 (16.7%)
Objective response rate	15.0%	33.3%
95% confidence interval	5.2 ; 36.0	9.7 ; 70.0
TPS 1-49%	n=19	n=11
Best overall response		
Complete response	0	0
Partial response	11 (57.9%)	7 (63.6%)
Stable disease	6 (31.6%)	0
Progressive disease	1 (5.3%)	2 (18.2%)
Not evaluable	0	1 (9.1%)
Missing	1 (5.3%)	1 (9.1%)
Objective response rate	57.9%	63.6%
95% confidence interval	36.3 ; 76.9	35.4 ; 84.8